The clinical progression of new chemical entities to pharmaceuticals remains hindered by the relatively slow pace of technology development in toxicology and clinical safety evaluation, particularly in vitro approaches, that can be used in the preclinical and early clinical phases of drug development. To alleviate this bottleneck, we have developed a metabolizing enzyme toxicology assay chip (MetaChip) that combines high-throughput P450 catalysis with cell-based screening on a microscale platform. The MetaChip concept is demonstrated by using sol-gel encapsulated P450s to activate the prodrug cyclophosphamide, which is the major constituent of the anticancer drug Cytoxan, as well as other compounds that are activated by P450 metabolism. The MetaChip provides a high-throughput microscale alternative to currently used in vitro methods for human metabolism and toxicology screening based on liver slices, cultured human hepatocytes, purified microsomal preparations, or isolated and purified P450s. This technology creates opportunities for rapid and inexpensive assessment of ADME͞Tox (absorption, distribution, metabolism, excretion͞toxicology) at very early phases of drug development, thereby enabling unsuitable candidates to be eliminated from consideration much earlier in the drug discovery process.in situ drug metabolism ͉ in vitro cytotoxicity ͉ P450 ͉ sol-gel encapsulation I n the past decade, there has been a dramatic increase in the number of new chemical entities (NCEs) and screenable drug targets as a result of combinatorial chemistry and advances in genomics and proteomics (1-4). Nevertheless, these advances have not translated into an increased number of new drug approvals (5, 6), in part because of the high failure rate due to toxicity of the NCE or its metabolite(s) (7). Furthermore, screening for toxicity at early stages of the drug discovery process is precluded by the large number of compounds available at the lead discovery stage, forcing medicinal chemists to select compounds for lead optimization based on limited information about their toxicological properties. In particular, there remains a lack of in vitro techniques that can adequately mimic human metabolism and therefore assess cell-specific toxicity of NCEs and their metabolites at speeds consistent with high-throughput biological activity screening.The human body, primarily the liver, contains a variety of enzymes that are involved in the metabolism of the myriad chemicals that comprise today's pharmaceuticals. By far the most important class of metabolic enzymes is the cytochromes P450, which are directly involved in the initial (or ''first-pass'') clearance of drugs from the body (8, 9). During this process, drug metabolites are generated, some of which are biologically active in their own right and exert the desired pharmacological effect. For example, conversion of the antihistamine loratadine to descarboethoxyloratadine by CYP2D6 and CYP3A4 is required for biological activity (10). Often, however, drug metabolism can lead to undesirable ...